Cargando…

Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach

Introduction: Hydrocortisone is the standard of care in cortisol replacement therapy for congenital adrenal hyperplasia patients. Challenges in mimicking cortisol circadian rhythm and dosing individualization can be overcome by the support of mathematical modelling. Previously, a non-linear mixed-ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Michelet, Robin, Bindellini, Davide, Melin, Johanna, Neumann, Uta, Blankenstein, Oliver, Huisinga, Wilhelm, Johnson, Trevor N., Whitaker, Martin J., Ross, Richard, Kloft, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877293/
https://www.ncbi.nlm.nih.gov/pubmed/36712688
http://dx.doi.org/10.3389/fphar.2022.1090554
_version_ 1784878334301175808
author Michelet, Robin
Bindellini, Davide
Melin, Johanna
Neumann, Uta
Blankenstein, Oliver
Huisinga, Wilhelm
Johnson, Trevor N.
Whitaker, Martin J.
Ross, Richard
Kloft, Charlotte
author_facet Michelet, Robin
Bindellini, Davide
Melin, Johanna
Neumann, Uta
Blankenstein, Oliver
Huisinga, Wilhelm
Johnson, Trevor N.
Whitaker, Martin J.
Ross, Richard
Kloft, Charlotte
author_sort Michelet, Robin
collection PubMed
description Introduction: Hydrocortisone is the standard of care in cortisol replacement therapy for congenital adrenal hyperplasia patients. Challenges in mimicking cortisol circadian rhythm and dosing individualization can be overcome by the support of mathematical modelling. Previously, a non-linear mixed-effects (NLME) model was developed based on clinical hydrocortisone pharmacokinetic (PK) pediatric and adult data. Additionally, a physiologically-based pharmacokinetic (PBPK) model was developed for adults and a pediatric model was obtained using maturation functions for relevant processes. In this work, a middle-out approach was applied. The aim was to investigate whether PBPK-derived maturation functions could provide a better description of hydrocortisone PK inter-individual variability when implemented in the NLME framework, with the goal of providing better individual predictions towards precision dosing at the patient level. Methods: Hydrocortisone PK data from 24 adrenal insufficiency pediatric patients and 30 adult healthy volunteers were used for NLME model development, while the PBPK model and maturation functions of clearance and cortisol binding globulin (CBG) were developed based on previous studies published in the literature. Results: Clearance (CL) estimates from both approaches were similar for children older than 1 year (CL/F increasing from around 150 L/h to 500 L/h), while CBG concentrations differed across the whole age range (CBG(NLME) stable around 0.5 μM vs. steady increase from 0.35 to 0.8 μM for CBG (PBPK)). PBPK-derived maturation functions were subsequently included in the NLME model. After inclusion of the maturation functions, none, a part of, or all parameters were re-estimated. However, the inclusion of CL and/or CBG maturation functions in the NLME model did not result in improved model performance for the CL maturation function (ΔOFV > −15.36) and the re-estimation of parameters using the CBG maturation function most often led to unstable models or individual CL prediction bias. Discussion: Three explanations for the observed discrepancies could be postulated, i) non-considered maturation of processes such as absorption or first-pass effect, ii) lack of patients between 1 and 12 months, iii) lack of correction of PBPK CL maturation functions derived from urinary concentration ratio data for the renal function relative to adults. These should be investigated in the future to determine how NLME and PBPK methods can work towards deriving insights into pediatric hydrocortisone PK.
format Online
Article
Text
id pubmed-9877293
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98772932023-01-27 Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach Michelet, Robin Bindellini, Davide Melin, Johanna Neumann, Uta Blankenstein, Oliver Huisinga, Wilhelm Johnson, Trevor N. Whitaker, Martin J. Ross, Richard Kloft, Charlotte Front Pharmacol Pharmacology Introduction: Hydrocortisone is the standard of care in cortisol replacement therapy for congenital adrenal hyperplasia patients. Challenges in mimicking cortisol circadian rhythm and dosing individualization can be overcome by the support of mathematical modelling. Previously, a non-linear mixed-effects (NLME) model was developed based on clinical hydrocortisone pharmacokinetic (PK) pediatric and adult data. Additionally, a physiologically-based pharmacokinetic (PBPK) model was developed for adults and a pediatric model was obtained using maturation functions for relevant processes. In this work, a middle-out approach was applied. The aim was to investigate whether PBPK-derived maturation functions could provide a better description of hydrocortisone PK inter-individual variability when implemented in the NLME framework, with the goal of providing better individual predictions towards precision dosing at the patient level. Methods: Hydrocortisone PK data from 24 adrenal insufficiency pediatric patients and 30 adult healthy volunteers were used for NLME model development, while the PBPK model and maturation functions of clearance and cortisol binding globulin (CBG) were developed based on previous studies published in the literature. Results: Clearance (CL) estimates from both approaches were similar for children older than 1 year (CL/F increasing from around 150 L/h to 500 L/h), while CBG concentrations differed across the whole age range (CBG(NLME) stable around 0.5 μM vs. steady increase from 0.35 to 0.8 μM for CBG (PBPK)). PBPK-derived maturation functions were subsequently included in the NLME model. After inclusion of the maturation functions, none, a part of, or all parameters were re-estimated. However, the inclusion of CL and/or CBG maturation functions in the NLME model did not result in improved model performance for the CL maturation function (ΔOFV > −15.36) and the re-estimation of parameters using the CBG maturation function most often led to unstable models or individual CL prediction bias. Discussion: Three explanations for the observed discrepancies could be postulated, i) non-considered maturation of processes such as absorption or first-pass effect, ii) lack of patients between 1 and 12 months, iii) lack of correction of PBPK CL maturation functions derived from urinary concentration ratio data for the renal function relative to adults. These should be investigated in the future to determine how NLME and PBPK methods can work towards deriving insights into pediatric hydrocortisone PK. Frontiers Media S.A. 2023-01-12 /pmc/articles/PMC9877293/ /pubmed/36712688 http://dx.doi.org/10.3389/fphar.2022.1090554 Text en Copyright © 2023 Michelet, Bindellini, Melin, Neumann, Blankenstein, Huisinga, Johnson, Whitaker, Ross and Kloft. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Michelet, Robin
Bindellini, Davide
Melin, Johanna
Neumann, Uta
Blankenstein, Oliver
Huisinga, Wilhelm
Johnson, Trevor N.
Whitaker, Martin J.
Ross, Richard
Kloft, Charlotte
Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
title Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
title_full Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
title_fullStr Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
title_full_unstemmed Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
title_short Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
title_sort insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877293/
https://www.ncbi.nlm.nih.gov/pubmed/36712688
http://dx.doi.org/10.3389/fphar.2022.1090554
work_keys_str_mv AT micheletrobin insightsinthematurationalprocessesinfluencinghydrocortisonepharmacokineticsincongenitaladrenalhyperplasiapatientsusingamiddleoutapproach
AT bindellinidavide insightsinthematurationalprocessesinfluencinghydrocortisonepharmacokineticsincongenitaladrenalhyperplasiapatientsusingamiddleoutapproach
AT melinjohanna insightsinthematurationalprocessesinfluencinghydrocortisonepharmacokineticsincongenitaladrenalhyperplasiapatientsusingamiddleoutapproach
AT neumannuta insightsinthematurationalprocessesinfluencinghydrocortisonepharmacokineticsincongenitaladrenalhyperplasiapatientsusingamiddleoutapproach
AT blankensteinoliver insightsinthematurationalprocessesinfluencinghydrocortisonepharmacokineticsincongenitaladrenalhyperplasiapatientsusingamiddleoutapproach
AT huisingawilhelm insightsinthematurationalprocessesinfluencinghydrocortisonepharmacokineticsincongenitaladrenalhyperplasiapatientsusingamiddleoutapproach
AT johnsontrevorn insightsinthematurationalprocessesinfluencinghydrocortisonepharmacokineticsincongenitaladrenalhyperplasiapatientsusingamiddleoutapproach
AT whitakermartinj insightsinthematurationalprocessesinfluencinghydrocortisonepharmacokineticsincongenitaladrenalhyperplasiapatientsusingamiddleoutapproach
AT rossrichard insightsinthematurationalprocessesinfluencinghydrocortisonepharmacokineticsincongenitaladrenalhyperplasiapatientsusingamiddleoutapproach
AT kloftcharlotte insightsinthematurationalprocessesinfluencinghydrocortisonepharmacokineticsincongenitaladrenalhyperplasiapatientsusingamiddleoutapproach